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 Abstract 
Background and Aims 
Extra-intestinal manifestations are well recognised in IBD. To what extent the 
commonly recognised extra-intestinal manifestations seen in IBD patients are 
attributable to IBD is however not clear due to the limited number of controlled 
studies published.  
Methods 
We have conducted a study of these manifestations using electronic primary care 
records. We have identified extra-intestinal manifestations in IBD and non-IBD 
patients, and derived odds ratios (ORs) using conditional logistic regression.  
Results  
56,097 IBD patients (32.5% Crohn's disease, 48.3% UC and 19.2% not classified) 
were matched to 280,382 non-IBD controls.  We found records of Pyoderma 
Gangrenosum (odds ratio = 29.24), Erythema Nodosum (OR = 5.95), PSC (OR = 
188.25), Uveitis (OR = 2.81), Ankylosing Spondylitis (OR = 7.07), Sacroiliitis (OR = 
2.79) and non-Rheumatoid inflammatory arthritides (OR = 2.66) to be associated with 
IBD. One or more of these was recorded in 8.1% of IBD patients  and 2.3% of 
controls. Non-specific arthritides were present in many more patients, affecting 30% 
of IBD patients and 23.8% of controls overall. We also found weaker associations 
with a number of conditions not generally considered to be extra-intestinal 
manifestations including Psoriasis, Ischaemic Heart Disease, Multiple Sclerosis and 
hay fever. 
Conclusion  
Although “classical” extra-intestinal manifestations are strongly associated with IBD, 
most IBD patients remain unaffected. Arthropathies, perceived to be the commonest 
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extra-intestinal manifestation, are not strongly associated with IBD, and the 
proportion of arthropathies attributable to IBD is likely to be small. 
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Introduction 
It is well recognised that Inflammatory Bowel Disease (IBD) is associated with an 
increased risk of a number of extraintestinal diseases. Some of these such as 
Venous Thrombo-embolism (VTE) are regarded as complications of the disease 
process, whereas others are considered to be extraintestinal features of the 
underlying disease process. These extraintestinal manifestations (EIMs) usually 
include skin manifestations (pyoderma gangrenosum and erythema nodosum), joint 
manifestations (ankylosing spondylitis and seronegative arthritis), eye manifestations 
(iritis), and apthous ulceration of the mouth. Primary Sclerosing Cholangitis (PSC) is 
sometimes considered as part of this group. Though there is an extensive literature 
describing the association of complications with IBD, demonstrating for example that 
VTE is 3-4 times more common in patients with IBD than in the general population 
[1,2], the number of controlled studies of extra intestinal manifestations available are 
remarkably few[3,4]. Most of the literature constitutes case series or cohort studies  
of IBD patients describing the frequency of these manifestations, which does not 
allow us to examine variations in the frequency of these problems between patients 
with and without IBD[5,6]. It is believed from these studies  that extra-intestinal 
manifestations affect about 40% of IBD patients[5,7]. To our knowledge only one 
other recent high quality epidemiological study has compared extra-intestinal 
manifestations (EIMs) in IBD to general population controls, but that study did not 
report on peripheral arthritis which is the most commonly reported EIM in many 
series[8]. 
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Since examination of the associations of IBD with EIMs has led to further insights into 
their aetiology [9,10], a clear understanding of the strengths of these associations is 
of importance. Equally, knowledge of their prevalence in the population is of value to 
allow provision of services since affected patients will have greater need of health 
services and in some instances may be at an increased risk of death[11]. To 
determine the strength of association between IBD and EIMs including arthritis and 
how commonly they occur, we have carried out a cross sectional study examining the 
comparative risks of a series of EIMs in both IBD and non-IBD patients. 
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Materials and Methods 
Data source 
The Clinical Practice Research Datalink (CPRD, formerly General Practice Research 
Database) is a prospectively gathered database of longitudinal records of 
consultations, diagnoses, investigations and referrals from UK primary care. Clinical 
data have been submitted by participating primary care practices since 1987. They 
are coded using the Read code system which is the standard coding system in UK 
general practice and provides hierarchical coding not only of diagnoses, but also 
signs, symptoms, interventions and a number of biographical and administrative 
items. CPRD has been widely used for epidemiological research, and the validity of 
diagnosis of IBD in these data has been specifically assessed[12], with 92% of 
diagnoses found highly probable and 95% at least probable. 
Study cohort 
We used CPRD records between 1987 and January 2011 to identify a cohort of 
patients with inflammatory bowel disease (IBD), based upon the presence of Read 
codes within their records indicating the diagnosis. These were matched on sex, date 
of birth (within 366 days) and GP practice with up to five patients without any records 
of an IBD diagnosis. Where more than five suitable controls were available, we 
selected randomly within the available controls. 
Covariates 
The associations between IBD and extra-intestinal manifestations are estimated with 
adjustment for body mass index (BMI) and tobacco use status so that these risk 
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factors for numerous diseases (including ischaemic heart disease, atrial fibrillation 
and hypertension) should not confound our estimates. 
We calculated a trimmed mean of BMI for each patient after removing values that fell 
outside the 1st- and 99th-centile. For patients without any records of BMI, we 
calculated BMI from their trimmed mean heights and weights. We categorised BMI as 
underweight (BMI under 18.5), normal (18.5–25), overweight (25–30), or obese (over 
30). We classified tobacco use for each patient as the highest recorded of the 
following status (from highest to lowest): “current smoker”, “ex-smoker”, or “not 
current”. We used an “unknown” category for missing values in body mass index or 
tobacco use, assuming that missingness did not occur at random.  
Extra-gastrointestinal manifestations 
Outcomes were defined in a similar manner to the diagnosis of IBD, by the presence 
of diagnostic codes for “red eyes” (divided into uveitis and non-uveitis causes), 
sclerosing cholangitis, psoriasis, erythema nodosum (both with and without 
sulphasalazine users to avoid conflating drug side effects with disease effects), 
pyoderma gangrenosum, arthropathies (divided into osteoarthritis, rheumatoid 
arthritis, ankylosing spondylitis, sacroiliitis and other specified inflammatory arthritis, 
arthritis not otherwise specified). Where previously validated code lists were not 
available we derived them by manually searching the list of Read codes. All lists were 
compiled by at least two of the authors.  
Patients with IBD are likely to consult their general practitioners more often than non-
IBD patients, which may lead to bias in the ascertainment of extra-gastrointestinal 
manifestations since these conditions may also occur in the general population. 
Hence, we have also examined the following conditions, which are not known to be 
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strongly associated with inflammatory bowel disease: atrial fibrillation, primary 
hypertension, ischaemic heart disease, hay fever, sinusitis, migraine and multiple 
sclerosis to ensure any study findings are not due to ascertainment bias. 
Statistical analysis 
We examined the association between the risk of developing any extra-
gastrointestinal manifestations and inflammatory bowel disease by estimating the 
odds ratio for each of the outcomes. Odds ratios (ORs) were estimated after 
adjusting for age, BMI and tobacco use in a multivariate conditional logistic 
regression model and are presented with 95% confidence intervals (CIs). 
Regulatory and ethical approval 
As this work utilised existing anonymised data, no separate ethical approval was 
required. The work was approved by the Independent Scientific Advisory Committee      
for MHRA database research; protocol number 10_147. 
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Results 
We identified a cohort of 56,097 IBD patients who had valid sex and date of birth 
recorded, and who contributed prospective data to CPRD. To these cases we 
matched 280,382 non-IBD patients.  
Half of the patients in our IBD cohort were diagnosed with ulcerative colitis and about 
one-third had Crohn's disease (Table 1) (the remaining IBD patients had either codes 
for both UC and Crohn’s or only codes for indeterminate or non-specific IBD). IBD 
patients were less likely to be current smokers (28.6% vs. 30.5%) and more likely to 
be ex-smokers (19.8% vs. 14.5%) than non-IBD patients. Non-IBD patients were 
more likely to be obese (14.6%) than IBD patients (13.1%). The proportion of non-
IBD patients with missing BMI or tobacco use status was higher, presumably due to 
fewer opportunities for these to be recorded. 
With the exception of hypertension, all of the extra-intestinal conditions we examined 
were more common in patients with IBD.  (Table 2). The association of IBD with 
extraintestinal disease was particularly strong for  uveitis (OR = 2.81, 95% CI = 2.65–
2.98), sclerosing cholangitis (OR = 188.25, 95% CI = 90.97–389.55), erythema 
nodosum (OR = 5.95, 95% CI = 5.38–6.59, and after excluding sulfasalazine users 
OR = 4.84, 95% CI = 4.35–5.39), pyoderma gangrenosum (OR = 29.24, 95% CI = 
20.99–40.75), ankylosing spondylitis (OR = 7.07, 95% CI = 6.24–8.01), sacroiliitis 
(OR = 2.79, 95% CI = 2.45–3.17), and other inflammatory arthritis (OR = 2.66, 95% 
CI = 2.44–2.91) (Table 3). The association was moderate between IBD and multiple 
sclerosis (OR = 1.45, 95% CI = 1.26–1.67), all arthropathies combined (OR = 1.47, 
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95% CI = 1.43–1.50) and psoriasis (OR=1.36, 95% CI=1.30-1.42). Although the 
associations were substantial, the proportion of IBD patients affected by each of  
those conditions was small: from 0.5% with pyoderma gangrenosum to 3.4% with 
uveitis. Overall 8.1% of IBD patients and 2.3 % of controls were affected by at least 
one of these well recognised associations, i.e. an excess of 5.8% among IBD 
patients. Many IBD patients had presented to their GP with arthropathy (n = 16,854, 
30.0%) or a red eye (n = 12,102, 21.6%), but most of those were attributed to non-
specific arthritis (n = 11,585) or non-uveitis causes of red eye (n = 11,073). 
Crohn's disease was more strongly associated with uveitis (OR = 3.20, 95% CI = 
2.89–3.55), ankylosing spondylitis (OR = 8.98, 95% CI = 7.18–11.23), or cutaneous 
manifestations such as erythema nodosum (OR = 9.08, 95% CI = 7.70–10.71 and 
after excluding sulfasalazine users: OR = 7.74, 95% CI = 6.52–9.17) and pyoderma 
gangrenosum (OR = 47.36, 95% CI = 21.94–102.26) (Table 3). Ulcerative colitis was 
more strongly associated with sclerosing cholangitis (OR = 313.71, 95% CI = 93.96–
1,047.36) than Crohn's disease, although the number of patients affected was small 
(37 Crohn's disease and 227 ulcerative colitis patients). 
Patients with IBD were also more likely to have atrial fibrillation (OR = 1.11, 95% CI = 
1.05–1.16), ischaemic heart disease (OR = 1.21, 95% CI = 1.17–1.26), migraine (OR 
= 1.13, 95% CI = 1.09–1.17), psoriasis ( OR = 1.36, 95% CI = 1.3-1.42) or multiple 
sclerosis (OR = 1.45, 95% CI = 1.26–1.67) (Table 3). 
It was notable that with the exceptions of psoriasis and multiple sclerosis all 
extraintestinal conditions studied were more commonly diagnosed after than before 
IBD. This was particularly marked for sclerosing cholangitis which was 5 times as 
commonly diagnosed after IBD (tables 4 and 5). 
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Discussion 
We have shown that the commonly recognised extra-intestinal manifestations of IBD 
are indeed more commonly diagnosed in IBD patients than in the general population. 
The degree to which they are associated with IBD varies, with the strongest 
associations being for sclerosing cholangitis, pyoderma gangrenosum and erythema 
nodosum, with uveitis and sero-negative arthropathy (except ankylosing spondylitis, 
which is strongly associated with IBD) being less closely associated. We have also 
shown that these associations are reasonably specific to the classically recognised 
extra-intestinal manifestations, and that the proportion of IBD cases affected with 
sufficient severity to be reported to a general practitioner is in absolute terms only 
greater than that in controls by about 6%. 
 
Strengths and weaknesses 
With 56,097 IBD cases and 280,382 general population controls, ours is the largest 
study of EIMs yet conducted. This provides us with power to subdivide the 
manifestations studied and to examine the associations with rare diagnoses such as 
pyoderma gangrenosum and PSC. We are enabled to have this power by our use of 
routinely collected clinical data from general practitioners, which also allows us to 
ensure that our populations of cases and controls have been selected with minimal 
bias. This ensures that, unlike previous studies from tertiary referral centres, our 
results should be generalisable to the whole UK population. Using this data source 
does however have an appreciable scientific cost: we do not have the ability to 
validate the diagnoses we are describing for individual patients, or to subdivide them 
into more specific categories.  This is not to say that the diagnostic information is 
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unreliable. A number of the diagnoses we studied have been specifically validated in 
this data set[11,12] by reference to paper records, and the plethora of validated 
diagnoses[13,14] suggest that GP recorded diagnoses are generally accurate in 
about 90% of patients. We cannot however divide arthropathy into large and small 
joint diseases, determine the extent of skin involvement in PG or psoriasis, or define 
a detailed phenotype of IBD. Perhaps most importantly when considering the 
differences between our findings and those of previous studies, we cannot closely 
examine patients for evidence of subclinical presentations of the diagnoses we are 
studying. Therefore any such asymptomatic or subclinical presentations may be 
unrecorded when compared to previous studies. As this will affect both IBD cases 
and the control population equally it will not however have biased out comparison 
between them. 
 
Compared to past literature 
Occurrence of EIMs  
As for so many features of IBD, the earliest publications about the associations of 
IBD with its extra-intestinal manifestations were case reports and case series in the 
first half of the twentieth century[15–17]. The currently recognised associations were 
described very rapidly. Subsequently many groups have sought out extra-intestinal 
manifestations in the IBD patients under their care, or IBD in those with arthritis. Few 
studies however have included control groups and only one to our knowledge 
included general population controls in whom extra-intestinal manifestations were 
sought in the same manner as in IBD patients[8].  
15 
We find uveitis to be recorded in 3.4% of our IBD cases which is within the range of 
values (1.8-6%) found in large modern series[5,6,8,18]. For arthropathy overall, we 
report 30% of our IBD patients as being affected, which is amongst the higher figures 
reported. For a number of other EIMs, including EN, PG, PSC and AS, we report 
prevalence lower than in some previous studies. The reasons for this discrepancy 
may include the fact that we have included all patients with IBD regardless of the 
length of their history, whilst it is recognised that EIMs may appear more common if 
one waits many years after diagnosis [6,8]. Equally it may be that as many of the 
previous studies have been conducted from single centres with an interest in IBD, 
some cases which will be subclinical, and hence undetected, in the routine practice 
we describe will have been detected. One observation which might lend weight to this 
idea is that our figures are rather more similar to more dated British figures from an 
era before extra-intestinal manifestations might have been expected to be sought out 
by the clinician[19]. It is of course also possible that these conditions are left 
undetected in the UK despite causing symptoms, and finally it may be that we are 
seeing a different spectrum of disease due to the presence in our more recent cohort 
of milder IBD which would in the past itself have remained undiagnosed, or even 
because of the success  of modern IBD management in suppressing these problems. 
With respect to the variation between UC and CD we find, as is commonly reported, 
that apart from PSC, most EIMs are commoner in CD[5,6,18] and they occur / 
emerge after the diagnosis of IBD.  
Association with IBD 
One great advantage of the present study is the presence of general population 
controls, which allows determination of the degree of association between the 
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conditions studied and IBD. For each of the classically recognised EIMs we have 
considered there is a significant association with an odds ratio above 2. It is 
interesting to note however that a number of other conditions not commonly thought 
of as EIMs which we included primarily to consider specificity are also statistically 
significantly associated though with a lower OR. In some of these conditions, such as 
OA or RA, this may represent evidence of the misdiagnosis of a clinically similar EIM, 
but in others such as hay fever, sinusitis or migraine it is most reasonable to see this 
as evidence of ascertainment bias perhaps because increased medical contact 
increases the opportunity for diagnoses in those followed up with IBD. For ischaemic 
heart diseases and multiple sclerosis, it might be argued that they are neither related 
to a known EIM, nor certain not to be related to IBD. Each has previously been 
proposed to be associated with IBD[20,21], but neither is well recognised to be. Each 
condition is weakly associated with IBD, but unlike the classical EIMs, they do not 
appear to occur more commonly in IBD patients before their IBD is diagnosed. We 
believe therefore that ascertainment bias remains a possible explanation of these 
associations also. 
One other advantage of using controls of course is that we can speculate as to how 
much of an associated condition in IBD patients might be attributable to the IBD. The 
attributable risks of the extra-intestinal conditions (calculated making the assumption 
that the associations are causal) will be the risk in those with IBD minus that in the 
general population. For example overall arthropathy of one sort or another is reported 
by 30% of IBD patients, but was also reported by 24% of general population controls. 
We could argue therefore that in only about 6% at most of IBD patients is this likely to 
be truly an extra-intestinal manifestation of disease, or that only one fifth of the 
arthritis in IBD patients is likely to be related to it. If we compare this to PSC which is 
17 
very rare in the general population, though PSC occurs in only 0.6% of our IBD 
cohort, for almost 100% of these it is likely that the two conditions are related. 
 
Clinical implications 
For patients with IBD who present with EN, PG and PSC it is quite likely that the 
aetiology of these conditions may be closely linked to IBD. For patients with 
arthropathy, this link is far less likely and is in fact likely to be the case in no more 
than one fifth of cases. Previous reports of EIMs occurring in 40% or more of IBD 
cases are likely to have overestimated the prevalence of EIMs by including patients 
with arthropathy which was not truly related to IBD. Though IHD, MS and psoriasis 
which are not commonly seen as extra intestinal manifestations have been proposed 
to be associated with IBD, we find their associations to be a good deal weaker than 
those of the classical EIMs, and with odds ratios little higher than those found for 
associations with hay fever or migraine it is hard to rule out the possibilities of 
ascertainment bias or confounding as explanations. 
 
Summary 
We have found that commonly recognised skin, joint and eye extraintestinal 
manifestations of IBD occur in only about 6% more commonly in IBD cases than in 
the general population. Most arthropathy in IBD patients is unlikely to be a true 
extraintestinal manifestation. 
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  IBD patients 
Non-IBD 
patients 
  N = 56,097 N = 280,382 
  n % n % 
Type of IBD         
Crohn's disease 18,204 32.5     
Ulcerative colitis 27,108 48.3     
Not specified 10,785 19.2     
Male 26,283 46.9 131,352 46.8 
Mean age (years) 47.2 47.2 
Age group 
(years)     
0–20 2,658 4.7 13,291 4.7 
21–40 19,932 35.5 99,656 35.5 
41–60 18,325 32.7 91,625 32.7 
61–80 12,395 22.1 61,983 22.1 
over 80 2,787 5.0 13,827 4.9 
Body mass 
index     
0–18.5 1,967 3.5 6,751 2.4 
18.5–25.0 22,322 39.8 98,790 35.2 
25.0–30.0 15,392 27.4 76,443 27.3 
30.0–50.0 7,358 13.1 40,967 14.6 
Unknown 9,058 16.1 57,431 20.5 
Tobacco use         
Current 16,053 28.6 85,533 30.5 
Ex-smoker 11,130 19.8 40,732 14.5 
Non-current 25,120 44.8 126,969 45.3 
Unknown 3,794 6.8 27,148 9.7 
 
Table 1: Characteristics of patients, by inflammatory bowel disease status. 
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  All IBD patients Crohn's disease Ulcerative colitis 
  IBD patients Non-IBD patients IBD patients Non-IBD patients IBD patients Non-IBD patients 
  n % n % n % n % n % n % 
Ophthalmic                         
Red eye 12,102 21.6 51,635 18.4 3,704 20.3 16,242 17.8 5,608 20.7 24,894 18.4 
Non-uveitis 11,073 19.7 49,880 17.8 3,352 18.4 15,729 17.3 5,149 19.0 23,970 17.7 
Uveitis 1,890 3.4 3,392 1.2 636 3.5 1,009 1.1 811 3.0 1,733 1.3 
Hepatic                         
Sclerosing cholangitis 346 0.6 10 0.0 37 0.2 4 0.0 227 0.8 5 0.0 
Dermatological                         
Psoriasis 2,856 5.1 10,568 3.8 988 5.4 3,235 3.6 1,256 4.6 5,202 3.8 
Erythema nodosum 855 1.5 746 0.3 426 2.3 258 0.3 217 0.8 338 0.2 
excluding SSZ users 693 1.2 738 0.3 362 2.0 255 0.3 158 0.6 335 0.2 
Pyoderma gangrenosum 275 0.5 52 0.0 95 0.5 15 0.0 112 0.4 25 0.0 
Rheumatological                         
Osteoarthritis 7,728 13.8 36,265 12.9 1,937 10.6 9,818 10.8 4,284 15.8 19,769 14.6 
Rheumatoid arthritis 1,085 1.9 3,084 1.1 312 1.7 899 1.0 558 2.1 1,626 1.2 
Arthritis, NOS 11,585 20.7 44,397 15.8 3,472 19.1 12,761 14.0 5,420 20.0 22,949 16.9 
Ankylosing spondylitis 617 1.1 436 0.2 231 1.3 131 0.1 235 0.9 221 0.2 
Sacroiliitis 375 0.7 692 0.2 129 0.7 228 0.3 158 0.6 340 0.3 
Other inflammatory arthritis 795 1.4 1,478 0.5 295 1.6 472 0.5 300 1.1 720 0.5 
all arthropathies combined 16,854 30.0 66,786 23.8 4,886 26.8 18,952 20.8 8,346 30.8 35,191 26.0 
All IBD associated 4,548 8.1 6,536 2.3 1,614 8.9 2,032 2.2 1,867 6.9 3,247 2.4 
Other                         
Ischaemic heart disease 5,175 9.2 22,287 7.9 1,350 7.4 5,866 6.4 2,877 10.6 12,470 9.2 
Multiple sclerosis 265 0.5 913 0.3 89 0.5 302 0.3 128 0.5 427 0.3 
Sinusitis 8,580 15.3 40,254 14.4 2,530 13.9 12,872 14.1 4,037 14.9 19,063 14.1 
Migraine 4,380 7.8 19,376 6.9 1,430 7.9 6,545 7.2 1,892 7.0 8,738 6.5 
Hay fever 4,819 8.6 22,125 7.9 1,626 8.9 7,550 8.3 2,078 7.7 9,925 7.3 
Atrial fibrillation 2,165 3.9 9,903 3.5 554 3.0 2,570 2.8 1,260 4.6 5,680 4.2 
Hypertension 12,626 22.5 64,358 23.0 3,304 18.1 17,681 19.4 6,959 25.7 35,159 26.0 
Table 2: Proportion of IBD and non-IBD patients affected by conditions associated or not known to be associated with inflammatory 
bowel disease. 
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  All IBD patients Crohn's disease Ulcerative colitis 
  OR 95% CI OR 95% CI OR 95% CI 
Ophthalmic                   
Red eye 1.21 1.18 1.24 1.18 1.13 1.23 1.15 1.11 1.19 
Non-uveitis 1.12 1.10 1.15 1.08 1.03 1.13 1.08 1.04 1.11 
Uveitis 2.81 2.65 2.98 3.20 2.89 3.55 2.35 2.15 2.56 
Hepatic                   
Sclerosing cholangitis 188.25 90.97 389.55 60.36 15.89 229.33 313.71 93.96 1,047.36 
Dermatological                   
Psoriasis 1.36 1.30 1.42 1.53 1.42 1.65 1.23 1.15 1.31 
Erythema nodosum 5.95 5.38 6.59 9.08 7.70 10.71 3.26 2.74 3.89 
excludes SSZ users 4.84 4.35 5.39 7.74 6.52 9.17 2.39 1.97 2.90 
Pyoderma gangrenosum 29.24 20.99 40.75 47.36 21.94 102.26 26.67 16.13 44.12 
Rheumatological                   
Osteoarthritis 1.10 1.07 1.14 1.04 0.98 1.10 1.11 1.06 1.15 
Rheumatoid arthritis 1.76 1.64 1.89 1.70 1.49 1.94 1.74 1.57 1.92 
Arthritis, NOS 1.43 1.39 1.46 1.55 1.48 1.62 1.23 1.19 1.28 
Ankylosing spondylitis 7.07 6.24 8.01 8.98 7.18 11.23 5.32 4.41 6.42 
Sacroiliitis 2.79 2.45 3.17 2.90 2.31 3.63 2.42 1.99 2.94 
Other inflammatory 
arthritis 2.66 2.44 2.91 3.24 2.78 3.77 2.04 1.78 2.34 
all arthropathies combined 1.47 1.43 1.50 1.55 1.49 1.62 1.31 1.27 1.35 
All IBD associated 3.70 3.55 3.85 4.34 4.04 4.65 2.99 2.82 3.18 
Other                   
Ischaemic heart disease 1.21 1.17 1.26 1.21 1.13 1.30 1.21 1.15 1.27 
Multiple sclerosis 1.45 1.26 1.67 1.49 1.17 1.90 1.54 1.26 1.88 
Sinusitis 1.06 1.03 1.09 0.96 0.92 1.01 1.05 1.01 1.09 
Migraine 1.13 1.09 1.17 1.09 1.03 1.16 1.08 1.02 1.14 
Hay fever 1.06 1.02 1.10 1.08 1.02 1.14 1.00 0.95 1.05 
Atrial fibrillation 1.11 1.05 1.16 1.13 1.02 1.24 1.11 1.04 1.19 
Hypertension 0.96 0.93 0.98 0.95 0.90 1.00 0.95 0.91 0.98 
Table 3: Odds ratios for the studied associations adjusted for age, body mass index and tobacco use.  
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  Overall Before diagnosis date After diagnosis date 
  IBD patients Non-IBD patients IBD patients Non-IBD patients IBD patients Non-IBD patients 
  n % n % n % n % n % n % 
Ophthalmic                         
Red eye 12,102 21.6 51,635 18.4 4,704 8.4 31,702 11.3 7,398 13.2 19,933 7.1 
Non-uveitis 11,073 19.7 49,880 17.8 4,253 7.6 30,394 10.8 6,820 12.2 19,486 6.9 
Uveitis 1,890 3.4 3,392 1.2 659 1.2 2,102 0.7 1,231 2.2 1,290 0.5 
Hepatic                         
Sclerosing cholangitis 346 0.6 10 0.0 52 0.1 7 0.0 294 0.5 3 0.0 
Dermatological                         
Psoriasis 2,856 5.1 10,568 3.8 1,449 2.6 7,231 2.6 1,407 2.5 3,337 1.2 
Erythema nodosum 855 1.5 746 0.3 304 0.5 568 0.2 551 1.0 178 0.1 
excludes SSZ users 693 1.2 738 0.3 262 0.5 562 0.2 431 0.8 176 0.1 
Pyoderma gangrenosum 275 0.5 52 0.0 43 0.1 20 0.0 232 0.4 32 0.0 
Rheumatological                         
Osteoarthritis 7,728 13.8 36,265 12.9 2,729 4.9 20,280 7.2 4,999 8.9 15,985 5.7 
Rheumatoid arthritis 1,085 1.9 3,084 1.1 495 0.9 1,980 0.7 590 1.1 1,104 0.4 
Arthritis, NOS 11,585 20.7 44,397 15.8 3,674 6.5 24,271 8.7 7,911 14.1 20,126 7.2 
Ankylosing spondylitis 617 1.1 436 0.2 303 0.5 353 0.1 314 0.6 83 0.0 
Sacroiliitis 375 0.7 692 0.2 102 0.2 388 0.1 273 0.5 304 0.1 
Other inflammatory arthritis 795 1.4 1,478 0.5 217 0.4 880 0.3 578 1.0 598 0.2 
all arthropathies combined 16,854 30.0 66,786 23.8 6,109 10.9 39,441 14.1 10,745 19.2 27,345 9.8 
All IBD associated 4,548 8.1 6,536 2.3 1,525 2.7 4,163 1.5 3,023 5.4 2,373 0.8 
Other                         
Ischaemic heart disease 5,175 9.2 22,287 7.9 2,145 3.8 13,347 4.8 3,030 5.4 8,940 3.2 
Multiple sclerosis 265 0.5 913 0.3 132 0.2 678 0.2 133 0.2 235 0.1 
Sinusitis 8,580 15.3 40,254 14.4 3,284 5.9 24,910 8.9 5,296 9.4 15,344 5.5 
Migraine 4,380 7.8 19,376 6.9 2,107 3.8 13,775 4.9 2,273 4.1 5,601 2.0 
Hay fever 4,819 8.6 22,125 7.9 2,434 4.3 15,998 5.7 2,385 4.3 6,127 2.2 
Atrial fibrillation 2,165 3.9 9,903 3.5 480 0.9 4,124 1.5 1,685 3.0 5,779 2.1 
Hypertension 12,626 22.5 64,358 23.0 4,711 8.4 38,106 13.6 7,915 14.1 26,252 9.4 
Table 4: Frequency of associations between of extra-gastrointestinal manifestations and IBD, before and after diagnosis. 
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  Before diagnosis date After diagnosis date 
  OR 95% CI OR 95% CI 
Ophthalmic             
Red eye 0.69 0.67 0.72 2.04 1.98 2.10 
Non-uveitis 0.65 0.62 0.67 1.89 1.83 1.95 
Uveitis 1.57 1.43 1.71 4.76 4.39 5.16 
Hepatic   
 
    
 
  
Sclerosing cholangitis 34.89 13.80 88.23 744.92 148.86 3,727.62 
Dermatological   
 
    
 
  
Psoriasis 0.99 0.94 1.05 2.14 2.01 2.28 
Erythema nodosum 2.73 2.37 3.14 16.97 14.12 20.41 
excludes SSZ users 2.37 2.04 2.75 13.19 10.92 15.94 
Pyoderma gangrenosum 12.87 6.88 24.06 39.30 26.10 59.19 
Rheumatological   
 
    
 
  
Osteoarthritis 0.62 0.59 0.65 1.70 1.64 1.77 
Rheumatoid arthritis 1.23 1.12 1.36 2.69 2.43 2.98 
Arthritis, NOS 0.72 0.69 0.75 2.24 2.18 2.31 
Ankylosing spondylitis 4.26 3.65 4.98 19.42 15.10 24.96 
Sacroiliitis 1.30 1.04 1.62 4.87 4.09 5.79 
Other inflammatory 
arthritis 1.21 1.04 1.40 4.95 4.39 5.58 
all arthropathies combined 0.71 0.69 0.73 2.39 2.33 2.45 
All IBD associated 1.85 1.74 1.96 6.80 6.42 7.20 
Other             
Ischaemic heart disease 0.77 0.73 0.81 1.85 1.77 1.94 
Multiple sclerosis 0.97 0.80 1.17 2.82 2.27 3.50 
Sinusitis 0.61 0.59 0.64 1.82 1.76 1.88 
Migraine 0.74 0.71 0.78 2.06 1.96 2.17 
Hay fever 0.72 0.69 0.75 1.94 1.84 2.04 
Atrial fibrillation 0.56 0.51 0.62 1.51 1.43 1.61 
Hypertension 0.51 0.49 0.53 1.69 1.64 1.75 
 
Table 5: Adjusted odds ratios for associations occurring pre and post diagnosis of 
IBD. 
 
